Liquid biopsy companies develop minimally invasive tests that analyse tumour-derived and other disease-associated material found in blood or bodily fluids. These technologies support earlier detection, treatment selection, response monitoring and the identification of disease recurrence.
This category includes companies working on:
Browse 33 UK liquid biopsy companies below.
Decentralised molecular and multiomic diagnostics as a service
Molomix Bioscience is a Welsh biotechnology company providing decentralised molecular and multiomic diagnostics for research, clinical and applied testing settings. The company offers subscription-based access to sequencing and molecular diagnostic platforms, supported by consumables, training and technical support.…
GCP-accredited oncology molecular diagnostics for clinical trials and research
The Cancer Molecular Diagnostics Laboratory is an ISO 15189-accredited molecular diagnostics facility within the University of Cambridge Department of Oncology, jointly funded by CRUK and NIHR. Operating to GCP and GCLP standards, it provides next-generation sequencing, circulating tumour DNA analysis, liquid biopsy…
Non-invasive oral cancer screening using genomics and cell-free DNA
Wisdom Bioscience is a biotechnology company developing a non-invasive oral cancer screening platform that integrates next-generation sequencing and cell-free DNA analysis with saliva-based sample collection. The platform is designed to enable early detection of oral cancer through routine dental appointments,…
Blood-based microRNA test for multi-cancer early detection
Xgenera is a diagnostics company developing a blood test for the early detection of multiple cancers from a single sample. The test measures circulating microRNA biomarkers using PCR-based methods and applies machine learning to identify signals from up to 12 common cancers before symptoms appear. The company is…
Solutions for genomics, diagnostics and precision medicine
QIAGEN is a global provider of sample preparation, molecular diagnostics, and genomics solutions for pharmaceutical, clinical, and research applications. Its UK headquarters at Citylabs 2.0, Manchester serves as the company's global centre of excellence for precision medicine and companion diagnostics, co-developing…
Liquid biopsy NGS kits and genomic diagnostic services
Nonacus is a developer of next-generation sequencing reagents and library preparation kits for liquid biopsy and tissue-based genomic analysis. Its target enrichment and cell-free DNA workflow products support cancer detection, treatment stratification, and longitudinal monitoring. Through its clinical services…
Infrared spectroscopy blood test for early multi-cancer detection
Dxcover is a clinical-stage biotechnology company developing a blood-based multi-cancer early detection test. Its platform applies infrared spectroscopy to a dried blood spot to capture a pan-omic biological signature spanning proteins, lipids, metabolites, and nucleic acids simultaneously. Machine learning algorithms…
Integrated NGS assays for genomic profiling of haematological malignancies
Univ8 Genomics is a Belfast-based genomics diagnostics company developing targeted next-generation sequencing assays for the integrated clinical characterisation of haematological malignancies. Its assays enable simultaneous detection of clonal rearrangements, chromosomal translocations, copy number alterations and…
Proteomics and AI liquid biopsy for early lung cancer detection
Oxford Cancer Analytics is a biotechnology company developing blood-based diagnostic tests for early cancer detection using high-throughput circulating proteome analysis and machine learning. Its platform identifies protein biomarker signatures from blood samples to support clinical decision-making in lung disease,…
Blood-based circulating tumour DNA tests for cancer
Inivata is a liquid biopsy company developing molecular tests for cancer using circulating tumour DNA from blood samples. Its sequencing-based assays identify tumour-associated genetic changes and have been used to investigate residual disease, recurrence and treatment response. The technology supports molecular…
Molecular assay platform for genomic profiling in cancer diagnostics
Biofidelity is a Cambridge-based genomic technology company developing molecular assays for cancer biomarker detection in tissue and liquid biopsy samples. Its proprietary platform enables ultra-sensitive detection of somatic mutations at low variant allele fractions using a simplified four-step qPCR workflow, without…
AI-driven liquid biopsy platform for early cancer biomarker discovery
BioMavericks is an early-stage biotechnology company developing an AI-driven liquid biopsy platform for the early detection of cancer. Its lead product targets the discovery and validation of blood-based biomarkers for early-stage pancreatic cancer diagnostics, integrating molecular cell biology, multi-omics data…
DNA methylation blood tests for ovarian and pancreatic cancers
GenoME Diagnostics is a biotechnology company developing molecular blood tests for cancer detection and monitoring. Its liquid biopsy platform identifies DNA methylation and fragmentomic biomarkers, combining them into multiplexed droplet digital PCR assays. Its lead test targets ovarian cancer recurrence and…
Blood-based CIZ1B biomarker test for early-stage lung cancer detection
Cizzle Biotechnology is a UK-based diagnostics company developing a non-invasive blood test for the early detection of lung cancer. The company's CIZ1B biomarker test identifies a stable plasma biomarker highly correlated with early-stage disease, offering an alternative to imaging or biopsy procedures. Cizzle's test…
Long-read RNA sequencing platform for cancer biomarker discovery and diagnostics
Wobble Genomics is a Scottish biotechnology company developing long-read RNA sequencing technologies for biomarker discovery and cancer diagnostics. Its core platform combines a biochemical method to enrich rare and low-abundance full-length RNA transcripts, with a bioinformatics pipeline for novel transcript…
Mitochondrial DNA liquid biopsy tests for cancer and disease detection
MDNA Life Sciences is a biotechnology company developing proprietary diagnostic tests based on mitochondrial DNA biomarkers. Its technology detects specific mitochondrial DNA deletions in blood and tissue samples as indicators of disease, enabling non-invasive testing for conditions that are difficult to diagnose.…
Raman spectroscopy blood test for early cancer detection
CanSense is a Welsh biotechnology company developing a non-invasive blood test for the early detection of bowel and other cancers. The platform combines Raman laser spectroscopy with artificial intelligence to identify cancer-associated metabolic signatures in blood, delivering results within 48 hours without…
AI epigenomics platform for neurodegenerative disease detection
Prima Mente is a biotechnology company developing large-scale biological foundation models to understand and detect neurodegenerative disease. The company generates proprietary multi-omic data including whole-epigenome sequencing, and trains transformer-based models on DNA methylation patterns in cell-free DNA to…
DNA nanorobot platform for nucleic acid detection and bioanalysis
Nanovery is a biotechnology company developing a patented Nucleic Acid Nanorobotics (NANs) platform for enzyme-free detection and quantification of nucleic acid targets. Synthetic DNA nanorobots generate fluorescent signals in response to specific sequences, enabling direct quantification of antisense…
3D genomics platform for blood-based clinical diagnostics and precision medicine
Oxford BioDynamics develops blood-based diagnostic tests and precision medicine tools using its proprietary 3D genomics platform. The technology analyses chromosome conformation to identify epigenomic biomarkers linked to disease, prognosis and treatment response. Commercial products include tests for immune…